A/Prof Emma Link
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
37 Scholarly works
0 Projects
HIGHLIGHTS
2024
Journal article
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
DOI: 10.1111/bju.161902023
Journal article
A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma
DOI: 10.1186/s13148-023-01427-72023
Conference Proceedings
The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer-Toxicity and interim efficacy data
DOI: 10.1200/jco.2023.41.16_suppl.36162023
Conference Proceedings
Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial
DOI: 10.1016/s0302-2838(23)01275-72022
Journal article
Increased risk of diaphragmatic herniation following esophagectomy with a minimally invasive abdominal approach
DOI: 10.1093/dote/doab0662022
Journal article
Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma.
DOI: 10.1200/jco.2022.40.16_suppl.45372021
Conference Proceedings
Ipilimumab plus nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma.
DOI: 10.1200/JCO.2021.39.15_suppl.4565
RECENT SCHOLARLY WORKS
2021
Conference Proceedings
A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)
DOI: 10.1158/1538-7445.sabcs20-gs2-042020
Conference Proceedings
Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)
DOI: 10.1200/jco.2020.38.6_suppl.4852018
Journal article
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre
DOI: 10.1007/s00280-018-3679-4